

## Re: Your request made under the Freedom of Information Act 2000

I am researching the usage of high-cost intra-vitreous treatments in Ophthalmology. Your answers to the following questions will be highly appreciated.

1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:

- Aflibercept
- Bevacizumab
- Brolocizumab
- Dexamethasone
- Ranibizumab

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- Aflibercept
- Bevacizumab
- Brolocizumab
- Dexamethasone
- Ranibizumab

3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

**Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**